^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NY-ESO-1 TCR

    i
    Other names: NY-ESO-1 TCR, anti-NY-ESO-1 TCR, Anti-NY ESO-1 mTCR PBL
    Associations

    News

    Trials
    Company:
    Gilead, National Cancer Institute
    Drug class:
    TCR modulator, NY ESO 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Southern California | Trial completion date: Apr 2027 --> Aug 2027 | Initiation date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    9ms
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Southern California | Trial completion date: Nov 2026 --> Apr 2027 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative • PGR negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    1year
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Southern California | Trial completion date: Apr 2026 --> Nov 2026
    Trial completion date • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PD-1 expression • PGR negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    1year
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Southern California | Trial primary completion date: Mar 2025 --> Oct 2025
    Trial primary completion date • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PD-1 expression • PGR negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    over1year
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Southern California
    New P1 trial • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PD-1 expression • PGR negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    2years
    Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. (PubMed, Nat Commun)
    Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. Analysis of tumor samples post-treatment illustrates lete-cel infiltration and a decrease in expression of macrophage genes, suggesting remodeling of the tumor microenvironment. Here we report potential predictive and pharmacodynamic markers of lete-cel response that may inform LDR, cell dose, and strategies to enhance anticancer efficacy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CTAG1B (Cancer/testis antigen 1B) • CCR7 (Chemokine (C-C motif) receptor 7) • IL15 (Interleukin 15)
    |
    letetresgene autoleucel (GSK3377794) • NY-ESO-1 TCR